ReviewMedical oncology (Northwood, London, England)2025
Mechanistic insights into the therapeutic potential of β-elemene on glioma and other central nervous system diseases.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomimetic PD-1-MSCs membrane-engineered nanoparticles for enhanced blood-brain barrier penetration and anti- glioma therapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The central nervous system (CNS) governs critical physiological processes, and its dysregulation drives severe pathologies, particularly glioma, a life-threatening malignancy with limited therapeutic options. β-elemene (ELE), the bioactive compound derived from Curcuma wenyujin, exhibits potent anti-glioma activity as both a monotherapy and in synergy with chemo- or radiotherapy. Beyond glioma, ELE demonstrates therapeutic versatility across CNS disorders, including traumatic brain injury, ischemic stroke, spinal cord injury, neuropathic pain, experimental autoimmune encephalomyelitis, and obesity-associated microbiota-gut-brain axis dysfunction. Mechanistically, modulation of key signaling pathways implicated in neoplastic proliferation, metastasis, neuroinflammation, apoptosis, and oxidative stress positions ELE as a promising candidate for repurposing traditional medicine in modern neurotherapeutics. This review synthesizes ELE's therapeutic efficacy, elucidates the underlying molecular mechanisms, and highlights outstanding questions to guide future research for ELE therapies, advocating for integrating traditional Chinese medicine-driven approaches into modern pharmacological innovation with favorable treatment outcomes.
Indexed as
Identifiers
40846815What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.